Cell-Based and Exosome Therapy in Diabetic Stroke. Journal of Thrombosis and Haemostasis, 16, 1423–1436. Flow cytometric analysis of extracellular vesicle subsets in plasma: impact of swarm by particles of non-interest. International Journal of Molecular Sciences, 17, 170.
![zetasizer nano software zetasizer nano software](https://www.advanceduninstaller.com/images/aup/13d82417917d96377856db0c6b23630f.jpg)
Focus on Extracellular Vesicles: Introducing the Next Small Big Thing. Vesiclepedia 2019: a compendium of RNA, proteins, lipids and metabolites in extracellular vesicles. V., Kang, T., Sanwlani, R., Van Deun, J., Hendrix, A., & Mathivanan, S. European Review for Medical and Pharmacological Sciences, 21, 2940–2956. Exosomes as biomarkers and therapeutic tools for type 1 diabetes mellitus.
ZETASIZER NANO SOFTWARE UPDATE
Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. C., Bach, J.-M., Bachurski, D., Baharvand, H., Balaj, L., Baldacchino, S., Bauer, N. D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin-Smith, G. International Journal of Biochemistry and Cell Biology, 87, 77–85. Mesenchymal stem cells and differentiated insulin producing cells are new horizons for pancreatic regeneration in type I diabetes mellitus. Advanced Pharmaceutical Bulletin, 6, 293–299.ĭomouky, A. Mesenchymal Stem Cell-Derived Exosomes: New Opportunity in Cell-Free Therapy. Pashoutan Sarvar, D., Shamsasenjan, K., & Akbarzadehlaleh, P. Vitro Cellular & Developmental Biology - Animal, 51, 866–878. In vitro evaluation of different protocols for the induction of mesenchymal stem cells to insulin-producing cells. Seyedi, F., Farsinejad, A., Moshrefi, M., & Nematollahi-Mahani, S. Downstream application of hUC-MSCs-sEVs will be further explored. Our study showed that sEVs from hUC-MSCs conditioned medium were successfully isolated and characterised.
![zetasizer nano software zetasizer nano software](https://blog.sysmex.nl/hs-fs/hubfs/27426984537_a492dc2f16_o.jpg)
Typical sEVs biomarkers such as CD9, CD63, CD81, HSP70 and TSG101 were also detected with western blotting. Populations of sEVs with CD9, CD63 and CD81 positive were detected with size distribution in the diameter of 63.2 to 162.5 nm.
![zetasizer nano software zetasizer nano software](https://img.medicalexpo.com/pdf/repository_me/94317/zetasizer-nano-series-perfomance-simplicity-versatility-141073_6m.jpg)
Phenotypic analysis by flow cytometry revealed that hUC-MSCs expressed MSC surface marker, including CD90, CD73, CD105, CD44 and exhibited the capacity for osteogenic, adipogenic and chondrogenic differentiation. Morphology of hUC-MSCs displayed as spindle-shaped, fibroblast-like adherent cells. The expression of surface and internal markers of sEVs was also assessed by western blotting. The sEVs’ size distribution, intensity within a specific surface marker population were measured with zetasizer or nanoparticle tracking analysis. SEVs were successfully isolated by ultrafiltration from the conditioned medium of hUC-MSCs. hUC-MSCs were characterised through analysis of morphology, immunophenotyping and multidifferentiation ability. The objective of this study is to develop a simple protocol to isolate and characterise small extracellular vesicles (sEVs) from human umbilical cord-derived MSCs (hUC-MSCs).